Peptidream Inc. has announced a new radiopharmaceutical candidate targeting cadherin-3 (CDH3) for the diagnosis and treatment of head and neck squamous cell carcinoma.

Peptidream Inc. has announced progression of an oral dual IL-17A and IL-17F macrocyclic peptide inhibitor for psoriasis, with the program entering the company’s clinical development portfolio.

Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery collaboration.

Peptidream Inc. has announced approval of a clinical research protocol for [64Cu]PD-29875, a Claudin 18.2-targeting 64Cu-labeled radiopharmaceutical, in patients with gastric cancer.

Carbonic anhydrase IX (CAIX, CA9) is a membrane-associated isoform of the α-carbonic anhydrase enzyme family, involved in pH regulation and the acidification of the tumor microenvironment (TME) in solid tumors. It is widely recognized as a marker of tumor hypoxia and serves as a prognostic indicator in multiple human cancers.

Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting up-front, near-term payments and R&D funding, could end up with about $1.5 billion in milestones and options payments plus tiered royalties on net sales.

Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting up-front, near-term payments and R&D funding, could end up with about $1.5 billion in milestones and options payments plus tiered royalties on net sales.

The milestone is for the identification of candidates meeting the predefined lead compound criteria, and follows the initial milestone achieved in December 2023.

Peptidream Inc. has released promising results from preclinical testing of its oral myostatin inhibitors, administered in combination with semaglutide, in a mouse model of obesity.